US FTC Approves Aurobindo Pharma's $250M Lannett Deal

Aurobindo Pharma's US unit won Federal Trade Commission approval to buy Lannett Company, a Pennsylvania-based generics maker, for $250 million on a cash-free, debt-free basis. The transaction is expected to close before the end of June 2026.

“This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our U.S.-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances,” Swami S. Iyer, chief executive officer of Aurobindo Pharma USA, said in a statement Monday.

Tim Crew, Lannett’s CEO, called the combination a chance to make the company’s medicines “even more affordable and accessible for patients everywhere.”

The deal adds a manufacturing site in Seymour, Indiana, that can scale production to roughly 4 billion doses per year. That capacity aligns with US policy goals to shore up domestic pharmaceutical supply chains, Aurobindo said.

Aurobindo expects the acquisition to be immediately accretive to group earnings per share, with cost efficiencies and SG&A synergies flowing from integration. The purchase also expands Aurobindo USA’s pipeline in complex generics and controlled substances.

The transaction signals the growing importance of onshore manufacturing capacity for Indian drugmakers targeting the US generics market. Lannett’s focus on non-opioid controlled substances positions Aurobindo to meet regulatory demand for alternatives to opioid-based pain treatments.